Method for Treating Refractory Cancer
OwnerHooshmand Sheshbaradaran, Rebecca Baerga +1inventors
InventorsHooshmand Sheshbaradaran, Rebecca Baerga, Jenel Cobb
Life of this patent
Estimating the term…
Abstract
Therapeutic methods for treating refractory cancers are disclosed comprising administering to a patient in need of treatment a compound of Formula (I) disclosed herein.
Claims6
1-9. (canceled)
A method of treating a cancer previously treated with a regimen comprising one or more drugs chosen from the group consisting of 5-FU, camptothecin, gefitinib, erlotinib, icotinib, temsirolimus and temozolomide, said method comprising administration of tris(8-quinolinolato)gallium(III), or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
A method of treating a colorectal cancer previously treated with a regimen comprising one or both of oxaliplatin and 5-FU, said method comprising administration of tris(8-quinolinolato)gallium(III), or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
A method of treating a melanoma previously treated with a regimen comprising temozolomide, said method comprising administration of tris(8-quinolinolato)gallium(III), or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
A method of treating lung cancer previously treated with a regimen comprising one or more drugs chosen from paclitaxel, erlotinib, icotinib and gefitinib, said method comprising administration of tris(8-quinolinolato)gallium(III), or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
A method of treating non-small cell lung cancer having an activating mutation in the KRAS gene, said method comprising administration of tris(8-quinolinolato)gallium(III), or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
Dependencies are inferred from the claim text.